EQS Voting Rights Announcement: BB BIOTECH AG
Disclosure of Shareholdings Notification ID: 95e58c52-be79-4dff-913a-3d312fe9da73
Notification of Collective Investment Schemes PART 1: LICENSEE Company name and head office of the licensee resp. for foreign collective investment schemes, which are not authorized for sale and are not dependent from a group of companies, company name and head office of the fund administration or the investment company: Company: UBS Fund Management (Switzerland) A City: Basel Country: Switzerland
PART 2: COLLECTIVE INVESTMENT SCHEME/S Name of collective investment scheme/s which hold/s individually 3% or more voting rights
PART 3: DATE AND REASON FOR THE REPORTING OBLIGATION Date of the act that creates the obligation to notify: 30.04.2024
Facts and circumstances triggering the obligation to notify (art. 22 para. 1 b FMIO-FINMA): Acquisition Sale Creation of a group Change in group composition Termination of a group Discretionary exercise of voting rights Securities lending and comparable transactions Exercise, non-exercise or expiration of derivative holdings Granting (writing) of derivative holdings Capital increase Capital reduction Ipso jure transfer or transfer due to a decision by a court or public authority Change in the information subject to the obligation to notify Other X If the participation falls below the threshold of 3% (purchase positions and sale positions), no indication in Part 4 or Part 5 is required. Total of voting rights <3% PART 4: PURCHASE POSITIONS PURSUANT TO ART. 14 PARA. 1 A FMIO-FINMA Total of all purchase positions: Total of all equity securities or equity related securities (item 1), number of voting rights that can be exercised at one's own discretion (item 3) and derivative holdings (item 4)
Basis of calculation (art. 14 para. 2 FMIO-FINMA): total number of voting rights pursuant to the entry in the commercial register (see Central Business Names Index) or Publication according to art. 115 para. 3 FMIO: 55,400,000
Of the equity securities mentioned in item 1 above, the following part is held due to securities lending and comparable transactions (art. 17 FMIO-FINMA):
The following voting rights were delegated by a third party and can be exercised at one's own discretion.
Voting rights Is the person who has full discretionary powers to exercise voting rights directly or indirectly controlled? Yes No
Conversion and share purchase rights (such as call-options according to art. 15 para. 2 a FMIO-FINMA), granted (written) share sale rights and other derivative holdings:
[4.1] [4.2] Total 2 Calculated on the basis of the total number of voting rights pursuant to the entry in the commercial register (art. 14 para. 2 FMIO-FINMA)
Of the derivative holdings mentioned in item 4 above, the following part is held due to securities lending and comparable transactions (art. 17 FMIO-FINMA):
Total of all sale positions: 55,400,000
Derivative holdings Share sale rights (such as put-options according to art. 15 para. 2 a FMIO-FINMA), granted (written) conversion and share purchase rights and other derivative holdings:
Total 2 Calculated on the basis of the total number of voting rights pursuant to the entry in the commercial register (art. 14 para. 2 FMIO-FINMA) 10.05.2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Language: | English |
| Company: | BB BIOTECH AG |
| Schwertstrasse 6 | |
| 8200 Schaffhausen | |
| Switzerland | |
| Internet: | www.bbbiotech.ch |
| End of News | EQS News Service |
1900663 10.05.2024 CET/CEST
